Labiotech.eu

News and Trends 2 May 2016

Genetic Diagnostic can cut number of Breast Cancer Patients needing Chemo in Half

Agendia’s shows remarkable clinical results for its genomic assay (MammaPrint) allowed 48% of early-stage breast cancer patients to be spared from chemotherapy. Agendia started out in 2003 as a spin-off from the Netherlands Cancer Institute to commercialize diagnostic tools for cancer. Its first product was MammaPrint, which uses DNA microarray technology to test the activity 70 genes that […]

May 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 30 Apr 2016

What happened this week? Biotech Pyramid, CEO Interviews, Anti-Ageing

1. Infographic: Which are the most Valuable Biotechs in Europe? 2. Interviewing the CEO who uses Probiotics as Needle-free Vaccines 3. Illumina is Suing over NGS Prenatal Screening… Again 4. Interviewing the CSO of the newly £100Bn fund willing to finally tackle Dementia 5. Anti-ageing DIY Gene Therapy may have worked – to an extent… 6. ITW with the […]

April 30, 2016 - 1 minutemin - By Philip Hemme

News and Trends 30 Apr 2016

BioArt : Julian Voss-Andreae Materialises Molecules through Metal Sculpture

Last week we also looked at molecular sculpture, but with the medium of Glass. Now we turn to metal work and the challenges of scaling up molecular design work with the German BioArtist Julian Voss-Andreae. Julian was originally a quantum physicist from Germany who studied in Berlin, Edinburgh and then Vienna before returning to the artist path […]

April 30, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 29 Apr 2016

Big Pharma invest massively in Biomanufacturing facilities

Sanofi is pumping €300M into its current manufacturing site in Belgium. This will support its antibody pipeline, with new laboratories of quality control and manufacturing sciences. Sanofi, France’s largest Pharma, seems to be betting more and more in biologics. Just a few years after buying Genzyme, it’s giving its subsidiary more prominence in their R&D. Now, […]

April 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Apr 2016

EU approves Combo-Drug for Metastatic Colorectal Cancer

Servier sees one of its combo-drug (trifluridine/tipiracil) approved by the European Commission, after showing a 2 month improvement in overall survival for metastatic Colorectal cancer. The largest private Pharma from France, Servier has well-known stake in innovative oncology therapies due to its role in the restructuring of Cellectis as a universal CAR-T Biotech – which looks extremely […]

April 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Apr 2016

French Biotech and Cambridge to improve Food Security with UK Grant

Meiogenix and the University of Cambridge will get fresh money to investigate how epigenomics impacts crop diversity – and how it can be engineered for better yields of wheat. Based in Paris, Meiogenix is developing breeding technologies – which already caught the eye of Bayer Crop Science. One of its platforms is SpiX, which increases the […]

April 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Apr 2016

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

I had the chance to talk with Tetsuyuki Maruyama, the CSO of the relatively new Dementia Discovery Fund – our final interview for #BioTrinity2016 in London. The high risk nature of doing trials for Dementia patients means in the past the market for this area of Neurodegenerative disease has been tough. However, the need for […]

April 28, 2016 - 1 minutemin - By Philip Hemme

News and Trends 27 Apr 2016

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 Apr 2016

French Pleodrug for Rare Neurological Disease opens up phase III trial in US

Pharnext is opening their first US study sites for a phase III trial in a rare neuropathy – a milestone in the development of Pharnext’s leading candidate. Based in Paris (France), Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. Pharnext uses network pharmacology to discover synergistic combinations of drugs […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 Apr 2016

CAR-T for Lupus with French-Italian Partnership

TxCell and Ospedale San Raffaele have partnered up to research a new treatment for Lupus, based on engineered regulatory T-cells (CAR-Treg). TxCell is developing immunotherapies based on the discovery of a type of T-cells that have anti-inflammatory properties – regulatory T lymphocytes (Tregs). Tregs have already yielded two candidates. Osave is currently on phase IIb […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 Apr 2016

Interviewing the CEO who uses Probiotics as Needle-free Vaccines

This is my first interview from BioTrinity 2016 in London. I met with Tom Johnston, CEO of Mucosis, to learn more about the needle-free vaccine platform he is developing. Mucosis is a biotechnology company based in Gröningen, Netherlands (a city we covered here for its medtech innovation). It was founded in 2007 and has raised over €20M so […]

April 27, 2016 - 1 minutemin - By Philip Hemme

News and Trends 26 Apr 2016

Illumina is Suing over NGS Prenatal Screening… Again

Genoma is being sued by Illumina over four patents covering technology for prenatal testing, that uses NGS to diagnose fetal defects. After suing Oxford Nanopore over porin technology, Illumina is back to another contentious field – their patents for a type of non-invasive prenatal testing (NIPT). Illumina has filed a patent infringement suit in the Federal […]

April 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Genetic Diagnostic can cut number of Breast Cancer Patients needing Chemo in Half

What happened this week? Biotech Pyramid, CEO Interviews, Anti-Ageing

BioArt : Julian Voss-Andreae Materialises Molecules through Metal Sculpture

Big Pharma invest massively in Biomanufacturing facilities

EU approves Combo-Drug for Metastatic Colorectal Cancer

French Biotech and Cambridge to improve Food Security with UK Grant

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

French Pleodrug for Rare Neurological Disease opens up phase III trial in US

CAR-T for Lupus with French-Italian Partnership

Interviewing the CEO who uses Probiotics as Needle-free Vaccines

Illumina is Suing over NGS Prenatal Screening… Again

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!